Reader TTS

ABSTRACT Prostate cancer is the second most common cancer diagnosed in men worldwide and, although advances in treatment options have extended the overall survival of these patients, bone

health issues remain a challenge throughout the continuum of care. Patients with prostate cancer are at high risk of skeletal complications from bone metastases and bone loss induced by

cancer treatments, such as androgen-deprivation therapy. The preservation of skeletal health might require the cooperation of urologists, oncologists, pain specialists, and other physicians

specializing in the treatment of prostate cancer. Complications resulting from bone loss and bone metastases can result in increased risk of fracture and death. Implementation of a

multidisciplinary approach for the management of bone health can, therefore, provide clinically meaningful benefits to patients with skeletal complications. The early diagnosis and treatment

of bone loss and bone metastases with bisphosphonates are critical for the maintenance of skeletal wellness and prevention of bone complications in patients with prostate cancer. KEY POINTS

* Bone health issues remain a challenge throughout the continuum of care in patients with prostate cancer * The early diagnosis and treatment with bisphosphonates of bone loss and bone

metastases in patients with prostate cancer are critical to maintain skeletal wellness and prevent bone complications * Although the use of biomarkers of bone metabolism, imaging techniques,

and adjuvant therapies for the diagnosis and treatment of skeletal complications are being developed, risk-assessment tools are needed for the identification of patients with prostate

cancer who are at an increased risk of skeletal disease * The cooperation of urologists, medical oncologists, radiation oncologists, and other specialists to ensure that bone health is

monitored and treated throughout the course of disease progression can optimize outcomes Access through your institution Buy or subscribe This is a preview of subscription content, access

via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy

this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: *

Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BONE HEALTH EFFECTS OF ANDROGEN-DEPRIVATION THERAPY AND

ANDROGEN RECEPTOR INHIBITORS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER Article Open access 07 October 2020 REAL-WORLD USE OF BONE MODIFYING AGENTS IN METASTATIC,

CASTRATION-RESISTANT PROSTATE CANCER Article 07 July 2022 THE IMPACT OF NOVEL HORMONAL AGENTS ON FRACTURE RISK IN PROSTATE CANCER PATIENTS: A NATIONWIDE POPULATION-BASED COHORT STUDY Article

Open access 04 November 2024 REFERENCES * Parkin DM _ et al_. (2005) Global cancer statistics, 2002. _CA Cancer J Clin_ 55: 74–108 Article  Google Scholar  * Tannock IF _ et al_. (2004)

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. _N Engl J Med_ 351: 1502–1512 Article  CAS  Google Scholar  * Petrylak DP _ et al_. (2004) Docetaxel

and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. _N Engl J Med_ 351: 1513–1520 Article  CAS  Google Scholar  * Preston DM _ et al_. (2002)

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. _Prostate Cancer Prostatic Dis_ 5: 304–310 Article  CAS  Google Scholar  * Shahinian VB _

et al_. (2005) Risk of fracture after androgen deprivation for prostate cancer. _N Engl J Med_ 352: 154–164 Article  CAS  Google Scholar  * Smith MR _ et al_. (2005) Gonadotropin-releasing

hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. _J Clin Oncol_ 23: 7897–7903 Article  CAS  Google Scholar  * Coleman RE (2004)

Bisphosphonates: clinical experience. _Oncologist_ 9 (Suppl 4): 14–27 Article  CAS  Google Scholar  * Saad F _ et al_. (2004) Long-term efficacy and safety of zoledronic acid in men with

advanced prostate cancer and bone metastases. Presented at _XIXth Congress of the European Association of Urology_ March 24–27, Vienna, Austria * Lipton A (2004) Pathophysiology of bone

metastases: how this knowledge may lead to therapeutic intervention. _J Support Oncol_ 2: 205–213 PubMed  Google Scholar  * Weinfurt KP _ et al_. (2005) The significance of skeletal-related

events for the health-related quality of life of patients with metastatic prostate cancer. _Ann Oncol_ 16: 579–584 Article  CAS  Google Scholar  * Oefelein MG _ et al_. (2002) Skeletal

fractures negatively correlate with overall survival in men with prostate cancer. _J Urol_ 168: 1005–1007 Article  Google Scholar  * Saad F _ et al_. (2006) Pathologic fractures and bone

markers are predictors of clinical outcome in patients with prostate cancer and bone metastases. Presented at _2006 Prostate Cancer Symposium_ February 24–26, San Francisco, CA, USA *

Noguchi M _ et al_. (2003) Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. _Br J Cancer_ 88: 195–201 Article  CAS

  Google Scholar  * Pummer K (2006) Therapy of hormone refractory prostate cancer. Presented at _21st Annual Congress of the European Association of Urology_ April 5–8, Paris, France *

Polascik TJ _ et al_. (2005) Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone

metastases. _Urology_ 66: 1054–1059 Article  Google Scholar  * Sternberg CN _ et al_. (2006) The medical management of prostate cancer: a multidisciplinary team approach. _BJU Int_ 99: 22–27

Article  Google Scholar  * (1999) The Royal College of Radiologists' Clinical Oncology Information Network. British Association of Urological Surgeons. Guidelines on the management of

prostate cancer. _Clin Oncol (R Coll Radiol)_ 11: S53–S88 * Aus G _ et al_. (2005) EAU guidelines on prostate cancer. _Eur Urol_ 48: 546–551 Article  CAS  Google Scholar  * Diamond TH _ et

al_. (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. _Cancer_ 100: 892–899 Article  Google Scholar  *

Dearnaley DP _ et al_. (2003) A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). _J Natl Cancer Inst_ 95:

1300–1311 Article  CAS  Google Scholar  * Saad F _ et al_. (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

_J Natl Cancer Inst_ 94: 1458–1468 Article  CAS  Google Scholar  * Smith JA Jr (1989) Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a

randomized, prospective, double-blind, placebo-controlled study. _J Urol_ 141: 85–87 Article  Google Scholar  * Ernst DS _ et al_. (2003) Randomized, double-blind, controlled trial of

mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. _J Clin Oncol_ 21: 3335–3342 Article  CAS 

Google Scholar  * Heidenreich A _ et al_. (2005) Ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Presented at _2005 Prostate Cancer

Symposium_ February 17–19, Orlando, FL, USA * Lipton A _ et al_. (2002) The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic

lesions: a comparison to pamidronate. _Cancer Invest_ 20 (Suppl 2): 45–54 Article  CAS  Google Scholar  * Small EJ _ et al_. (2003) Combined analysis of two multicenter, randomized,

placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. _J Clin Oncol_ 21: 4277–4284 Article  CAS  Google Scholar  * Major

PP _ et al_. (2000) Oral bisphosphonates: a review of clinical use in patients with bone metastases. _Cancer_ 88: 6–14 Article  CAS  Google Scholar  * Greenspan SL _ et al_. (2005) Bone loss

after initiation of androgen deprivation therapy in patients with prostate cancer. _J Clin Endocrinol Metab_ 90: 6410–6417 Article  CAS  Google Scholar  * Maillefert JF _ et al_. (1999)

Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. _J Urol_ 161: 1219–1222 Article  CAS  Google Scholar  * Smith MR _ et al_.

(2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. _J Urol_ 175: 136–139 Article  CAS  Google Scholar  * Saad F _ et al_. (2006)

Natural history and treatment of bone complications in prostate cancer. _Eur Urol_ 49: 429–440 Article  CAS  Google Scholar  * Higano C (2006) Androgen deprivation therapy: monitoring and

managing the complications. _Hematol Oncol Clin North Am_ 20: 909–923 Article  Google Scholar  * Kaneko Y _ et al_. (2006) Intermittent androgen deprivation therapy may prolong the duration

of androgen dependence of well-differentiated prostate cancer. _Hinyokika Kiyo_ 52: 259–264 PubMed  Google Scholar  * Sharifi N _ et al_. (2005) Androgen deprivation therapy for prostate

cancer. _JAMA_ 294: 238–244 Article  CAS  Google Scholar  * Nelson JB _ et al_. (2006) Once weekly oral alendronate prevents bone loss in men on androgen deprivation therapy for prostate

cancer. Presented at _2006 Prostate Cancer Symposium_ February 24–26, San Francisco, CA, USA * Smith MR _ et al_. (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced

bone loss in men with prostate cancer: a randomized controlled trial. _J Clin Endocrinol Metab_ 89: 3841–3846 Article  CAS  Google Scholar  * Smith MR _ et al_. (2003) Randomized controlled

trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. _J Urol_ 169: 2008–2012 Article  CAS  Google Scholar  * Casey R

_ et al_. (2006) Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy. Presented at _2006 Prostate Cancer Symposium_ February 24–26, San

Francisco, CA, USA * Padalecki SS _ et al_. (2003) Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid. Presented at _24th

Annual Meeting of the American Society of Bone and Mineral Research_ September 20–24, San Antonio, TX, USA * Mystakidou K _ et al_. (2005) Randomized, open label, prospective study on the

effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. _Med Oncol_ 22: 195–201 Article

  CAS  Google Scholar  * Saad F _ et al_. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate

cancer. _J Natl Cancer Inst_ 96: 879–882 Article  CAS  Google Scholar  * Serafini AN (2001) Therapy of metastatic bone pain. _J Nucl Med_ 42: 895–906 CAS  PubMed  Google Scholar  * Rosen LS

_ et al_. (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized,

Phase III, double-blind, placebo-controlled trial. _Cancer_ 100: 2613–2621 Article  CAS  Google Scholar  * Rosen LS _ et al_. (2004) Zoledronic acid is superior to pamidronate for the

treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. _Cancer_ 100: 36–43 Article  CAS  Google Scholar  * Rosen LS _ et al_. (2003) Zoledronic acid

versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and

Other Solid Tumors Study Group. _J Clin Oncol_ 21: 3150–3157 Article  CAS  Google Scholar  * Efstathiou E _ et al_. (2005) Combination of docetaxel, estramustine phosphate, and zoledronic

acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. _Urology_ 65: 126–130 Article  CAS  Google Scholar  * Fulfaro F _ et al_. (2005)

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. _J Chemother_ 17: 555–559 Article  CAS 

Google Scholar  * Ripamonti C _ et al_. (2006) Pain on movement and pain at rest decrease after zoledronic acid infusion in patients with bone metastases due to breast or prostate cancer. _J

Clin Oncol_ 24 (Suppl): 694s Google Scholar  * Stanculeanu DL _ et al_. (2006) Zoledronic acid treatment in osteocondensant bone metastasis prostate cancer patients. Presented at _2006

Prostate Cancer Symposium_ February 24–26, San Francisco, CA, USA * Wiktor-Jedrzejczak W (2005) Reduction of pain as the primary determinant of improved quality of life of cancer patients

receiving zoledronic acid (Zol) for bone involvement. _J Clin Oncol_ 23 (Suppl): 734s Google Scholar  * Smith MR _ et al_. (2005) Natural history of rising serum prostate-specific antigen in

men with castrate nonmetastatic prostate cancer. _J Clin Oncol_ 23: 2918–2925 Article  Google Scholar  * Saad F _ et al_. (2006) Predictors of clinical outcome in patients with bone

metastases from prostate cancer. _J Clin Oncol_ 24 (Suppl): 230s Google Scholar  * Eastham J _ et al_. (2005) Effect of zoledronic acid on bone pain and skeletal morbidity in patients with

advanced prostate cancer; analysis by baseline pain. _J Clin Oncol_ 23 (Suppl): 393s Google Scholar  * Murray R _ et al_. (2004) Clinical benefit of zoledronic acid for the prevention of

multiple skeletal complications in patients with prostate cancer, based on history of skeletal complications. Presented at _29th European Society for Medical Oncology Congress_ October

29–November 2 Vienna, Austria * Saad F _ et al_. (2006) Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases.

Presented at _2006 European Association of Urology 21st Annual Congress_ April 5–8, Paris, France * McKiernan JM _ et al_. (2004) Impact of skeletal complications on total medical care costs

in prostate cancer patients with bone metastases. _J Clin Oncol_ 22 (Suppl): 531 Google Scholar  * Botteman M _ et al_. (2006) Cost-effectiveness of zoledronic acid vs. pamidronate in the

management of hormone refractory prostate cancer (HRPC) patients with bone metastases. _J Clin Oncol_ 24 (Suppl): 649s Google Scholar  * Botteman MF _ et al_. (2005) Cost effectiveness of

intravenous (IV) zoledronic acid versus other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: a Markov model from the UK

perspective. _J Clin Oncol_ 23 (Suppl): 58s Google Scholar  * Saad F _ et al_. (2003) Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications

in patients with advanced prostate cancer metastatic to bone. Presented at _American Urological Association Annual Meeting_ April 26–May 1, Chicago, IL, USA * Farrugia MC _ et al_. (2006)

Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. _Laryngoscope_ 116: 115–120 Article  Google Scholar  * Ficarra G _ et al_. (2005)

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. _J Clin Periodontol_ 32: 1123–1128 Article  CAS  Google Scholar  * Marx RE _ et al_. (2005)

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. _J Oral Maxillofac Surg_ 63: 1567–1575 Article  Google

Scholar  * Melo MD and Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. _J Am Dent

Assoc_ 136: 1675–1681 Article  CAS  Google Scholar  * Mignogna MD _ et al_. (2006) Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. _J Clin Oncol_ 24: 1475–1477

Article  Google Scholar  * Olson KB _ et al_. (2005) Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. _Urology_ 66: 658 Article  Google

Scholar  * Pastor-Zuazaga D _ et al_. (2006) Osteonecrosis of the jaws and bisphosphonates. Report of three cases. _Med Oral Patol Oral Cir Bucal_ 11: E76–E79 PubMed  Google Scholar  *

Ruggiero SL _ et al_. (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. _J Oral Maxillofac Surg_ 62: 527–534 Article  Google Scholar  * Woo

SB _ et al_. (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaw. _Ann Intern Med_ 144: 753–761 Article  CAS  Google Scholar  * Hoff AO _ et al_. (2006)

Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. Presented at: _42nd Annual Meeting of the American Society of Clinical Oncology_ June 2–6, Atlanta, GA, USA

* Ruggiero S _ et al_. (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. _J Oncol Pract_ 2: 7–14 Article  Google

Scholar  * Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. _Cancer Treat Rev_ 27: 165–176 Article  CAS  Google Scholar  * Hillner BE _

et al_. (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. _J Clin Oncol_ 21: 4042–4057 Article  CAS

  Google Scholar  Download references ACKNOWLEDGEMENTS We acknowledge the assistance of Carol Sledz in the editorial preparation of this manuscript before submission. AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * F Saad is Professor of Surgery/Urology at the University of Montreal, QC, Canada., Fred Saad * CN Sternberg is Professor of Medical Oncology-Urology at La Sapienza

University, Rome, Italy., Cora N Sternberg Authors * Fred Saad View author publications You can also search for this author inPubMed Google Scholar * Cora N Sternberg View author

publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Fred Saad. ETHICS DECLARATIONS COMPETING INTERESTS F Saad has received funding

for clinical research from Novartis Pharmaceuticals Corporation and Sanofi Aventis and has participated in such advisory boards. CN Sternberg has participated in Novartis Pharmaceuticals

Corporation and Sanofi Aventis advisory boards. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Saad, F., Sternberg, C. Multidisciplinary management of

bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. _Nat Rev Urol_ 4 (Suppl 1), S3–S13 (2007). https://doi.org/10.1038/ncpuro0727 Download citation *

Received: 23 October 2006 * Accepted: 15 December 2006 * Issue Date: February 2007 * DOI: https://doi.org/10.1038/ncpuro0727 SHARE THIS ARTICLE Anyone you share the following link with will

be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative